The Brain May Have Spoken a Dead Language. DMT Is Trying to Translate It. • didof.dev

When a dose of DMT hits the bloodstream, it crosses into the brain in seconds. Within 30 seconds, the consensus world dissolves into what users describe as hyper-real alien landscapes populated by apparently intelligent entities—elves, insectoids, automata, complex machinery, futuristic cities. [Milt Strassman’s clinical trials]( https://jps ставок.studies.springer.com/article/10.1007/s13181-008-0038-7) gave 57 volunteers intravenous DMT and documented the phenomenology. What struck Strassman most was not the strange imagery but its consistency: despite wildly different personalities, expectations, and cultural backgrounds, the experiences converged on remarkably similar themes.

This is not what you’d expect from a classical psychedelic. Other psychedelics like psilocybin and LSD activate the same receptor—5HT2A—and produce variable, psychologically contingent experiences that depend heavily on set and setting. DMT doesn’t. At high enough doses, the experience overwhelms individual psychology. Users don’t report their own anxieties projected outward; they report encountering what feels like an independently existing world.

I’ve been working with the idea that human consciousness is a world-building system—a thalamocortical engine that constructs models of reality from sensory data and intrinsic patterns. This angle has shaped how I think about a 2013 paper by Andrew R. Gallimore, “Building Alien Worlds: A Theoretical Model of N,N-Dimethyltryptamine Action,” published in the Journal of Psychedelic Studies. Gallimore doesn’t propose that DMT is “just another psychedelic.” He proposes that DMT may be an endogenous ancestral neuromodulator—a molecule the brain once used during evolution to build a completely parallel set of neural connectivities, creating a second world-building mode that still exists in the adult brain but remains largely inaccessible.

Put more provocatively: the brain may have once spoken a dead language. DMT is the attempt to speak it again.

Key Takeaways

Andrew Gallimore’s 2013 model proposes DMT is an endogenous neuromodulator that the ancestral brain used to develop parallel thalamocortical connectivities for building “alien worlds,” switching between serotonin (consensus mode) and DMT (alien mode).
DMT is chemically the simplest possible psychedelic tryptamine—just two methyl groups on tryptamine—and yet it produces the most profound alterations of consciousness of any naturally occurring drug. No other classical psychedelic reliably generates the phenomenological features found in DMT reports.
Strassman’s 57-patient IV study documented recurring themes: machine elves, insectoid entities, futuristic cities, complex machinery, and the sensation of being experimented on. These themes appear consistently across independent trip reports and are notably absent in experiences with other psychedelics.
Gallimore argues that modern humans lost the ability to secrete DMT in psychedelic concentrations during evolution. The vestigial amounts still present in the brain may represent a functional remnant, and exhaling external DMT reconstitutes an ancestral state.

Why DMT Breaks the Classical Psychedelic Category

The standard model of psychedelia starts with the 5HT2A receptor. When LSD, psilocin, or mescaline bind to 5HT2A receptors in the prefrontal cortex, they trigger a cascade of effects: pattern disruption, altered perception, ego dissolution. The model works well enough for these molecules. DMT does not fit.

DMT’s affinity for 5HT2A lies between psilocin and LSD. From a pharmacological perspective, it’s unremarkable. But the phenomenological effects are not. DMT’s molecule is structurally the simplest possible psychedelic tryptamine—tryptamine with two methyl groups on the primary amine. That masking actually prevents the nitrogen from interacting with the 5HT2A receptor, as Ebersole, Visiers, Weinstein, and Sealfon demonstrated in 2003 . So DMT should be pharmacologically blunt. Instead, it is the most incomprehensibly powerful natural psychedelic known.

Three characteristics make DMT pharmacologically anomalous among classical psychedelics:

Speed of onset and clearance. When DMT enters the bloodstream, it rapidly sequesters into tissues including the brain, reaching psychedelic concentrations within seconds. The Shulgins showed that DMT is a transport substrate for both the serotonin transporter and the monoamine vesicular transporter ( Cozzi et al., 2009 ), meaning it may be actively transported into presynaptic terminals and packaged into synaptic vesicles for release. The trip itself is mercifully brief—minutes, not hours—far more rapidly cleared than other tryptamines.

No tolerance buildup. Repeated use does not generate tolerance. This is unique among classical psychedelics ( Strassman, Qualls, & Berg, 1996 ). Any drug users develop tolerance to eventually dose higher, but DMT users don’t. This is exactly the pattern you’d expect from an endogenous neurotransmitter rather than an exogenous drug.

Phenomenological specificity. DMT uniquely and reliably produces what users call “breakthrough” experiences—transitioning from early dissociative stages into fully formed, hyper-realistic alien worlds with apparently intelligent entities. No other psychedelic does this consistently.

The standard model cannot explain this. DMT sits at the bottom of the molecular complexity ladder, uniquely produces highly regular and specific phenomenological content, and behaves pharmacologically like an endogenous molecule. Any one of these facts alone would be notable. Together, they suggest something that most psychedelic research explicitly avoids considering: DMT may have a true neural function in the human brain.

What the Trip Reports Actually Say

Before I get to Gallimore’s model, I want to ground it in the raw data. Strassman’s clinical study is the most systematically documented source. Of his 57 volunteers, a significant proportion reported “breaking through” the initial stages—confusion, visual distortion, the sensation of being pulled apart—into a fully formed world. The recurring themes are strikingly consistent across independent reports:

Merry-go-rounds, fairgrounds, circuses;
Playful or mischievous entities described as elves, pixies, dwarves, or goblins;
Insectoid and reptilian creatures operating in technological environments;
Futuristic hypertechnological buildings and cities;
Complex machinery and hyper-advanced technology;
The sensation of being observed or experimented on.

The most consistently reported feature—the one that has generated the most cultural attention and the most skepticism—is the presence of apparently intelligent entities. Not symbolic projections. Not archetypal imagery. Entities that users describe as vastly more intelligent and capable than themselves, actively engaging, communicating, or experimenting with them:

“Trying to describe them isn’t easy. On one level I call them self-transforming machine elves; half machine, half elf. They move very quickly and change.” — Terence McKenna, 1993

“They kept saying ‘welcome back’ and words like: the big winner, he has returned, welcome to the end and the beginning, you are The One!” — Erowid Experience Report 1839

“There were creatures and machinery… there was a female who, when I felt I was dying, appeared and reassured me… She was showing me, it seemed, how to use this thing, which resembled a computer terminal.” — Strassman, Wojtowicz, Luna, & Frecska (2008)

Three observations stand out from these reports. First, the entities are not human. They are described as insectoid, machine-like,elf-like, or simply as overwhelming presences without identifiable form. Second, the users consistently describe the DMT world as more real than ordinary waking reality, even after the experience has ended. Third, lucidity is complete—there is no haziness or stoned confusion. The user experiences the content with what feels like ordinary waking clarity.

This third observation is the hardest to reconcile with a hallucination model. Hallucinations are, by definition, perceptual content generated without extrinsic stimulation. They should be recognizably unreal—like dreams. But DMT users don’t say “this feels like a really vivid dream.” They say “this is more real than the world I woke up from.” And the vast majority refuse to accept that the world they encountered was constructed by their brain.

Is the DMT World a Dream?

The dream hypothesis was the first serious attempt to explain DMT phenomenology in neurological terms. It goes like this: during REM sleep, the brain generates immersive worlds from intrinsic data without sensory modulation. Maybe DMT is the “dream molecule,” released in psychedelic concentrations during sleep, generating dreams. The neural activity of the waking state is fundamentally equivalent to the dream state—the key difference is only whether extrinsic sensory data modulates it.

Callaway proposed this formally in 1988, and McKenna discussed it frequently. But the hypothesis has a critical empirical problem: 69 published studies between 1955 and 2010 searched for DMT or its metabolites in the bodily fluids of psychiatric patients and controls. DMT was detected—but levels were erratic, generally not different from healthy controls, and critically, one study found no diurnal rhythm with peaks during sleep, as the dream hypothesis would predict.

But beyond the lack of physiological evidence, Gallimore asks a deeper phenomenological question: does the DMT experience actually resemble dreaming?

Dream reports are overwhelmingly continuous with waking life. Events in dreams reflect waking life, even mundane activities. Characters are from waking life—friends, family, colleagues. All sensory modalities are typically intact. The symbolic content of dreams, when it exists, tends toward themes from the dreamer’s own psychology: being pursued, falling, losing teeth, appearing naked in public.

The DMT world shares none of these features. Despite varying between individuals, high-dose DMT reports converge on themes completely unrelated to consensus reality—futuristic cities, non-human entities, complex machinery. The phenomenology is incomparable.

The Ancestral Neuromodulator Hypothesis

Gallimore’s model makes a specific claim about the architecture of the brain’s thalamocortical system. The connectivities of this system develop from three processes operating on different timescales: evolution, development, and individual experience. These connectivities are established by sampling sensory data from the external world. The brain learns to build the consensus world, and once developed, it can build that world in the presence or absence of sensory data—that’s waking and dreaming.

This development occurs in the presence of serotonin, which modulates the excitability of cortical pyramidal and inhibitory interneurons through 5HT1A and 5HT2A receptors. The intrinsic activity that builds the consensus world is expressed most reliably when serotonin is present. When the balance of 5HT1A/5HT2A activation shifts—such as under other psychedelics—the consensus set of connectivities breaks down, and the system becomes “re-potentiated,” capable of adopting unpredictable states.

DMT shifts this balance in the same direction as other psychedelics. But something different happens: the thalamocortical system does not behave unpredictably. Instead, it behaves as if its structural and functional connectivity had developed in the presence of DMT and subject to the sensory input of a completely different reality.

Which set is expressed depends on which neuromodulator is present. Serotonin expresses the consensus set; DMT expresses the alien set. The alien world’s intrinsic activity can only be generated in the presence of DMT, just as the consensus world appears in the presence of serotonin.

This model solves several puzzles simultaneously:

Why DMT is unique. DMT’s specificity is simply a consequence of it being the neuromodulator present when the alien-world connectivities were developed. Only DMT can shift the thalamocortical system into the correct state to express them.

Why the experience is regular and specific. The alien world’s connectivities developed through the same mechanism as the consensus world—by sampling extrinsic sensory data over evolutionary time. The extrinsic data came from an alternate reality (the model doesn’t specify what or how, it simply states that if such data existed and DMT was present, the connectivities would develop).

Why the brain doesn’t build these worlds now. If DMT has been lost as a primary neuromodulator, the consensus-world connectivities dominate. The alien-world connectivities remain as potential synapses—present in structure but not functionally expressed.

How Parallel World-Building Could Evolve

Gallimore’s model extends to a specific evolutionary scenario. The ancestral brain produced both serotonin and DMT, probably not simultaneously. During waking hours, serotonin modulated the thalamocortical system, building consensus-world connectivities driven by sensory data from the consensus world. During sleep, the brain switched to DMT secretion.

DMT’s 5HT1A/5HT2A binding signature facilitated intrinsic activity that matched sensory data from an alternate reality—what Gallimore calls the “alien world.” This wasn’t hallucination. The brain was receiving extrinsic data and developing connectivities to build that world, using the same mechanism by which it builds the consensus world. Over evolutionary time, two entirely separate world-building capabilities developed.

The model proposes a diurnal rhythm: serotonin during waking (consensus evolution), DMT during REM sleep (alien-world evolution). This would explain why the pineal gland—proposed as a site of endogenous DMT synthesis ( Strassman et al., 2008 )—is primarily nocturnal, secreting melatonin only during darkness. The pineal has been regarded since antiquity as a connection between material and spiritual worlds. Perhaps there is an element of truth in these “primitive” ideas.

Then, at some point in evolutionary history, the brain lost its ability to secrete DMT in psychedelic concentrations. Only serotonin remained. All knowledge of the alien world was effectively forgotten. Modern dreaming—the period when serotonin drops during REM sleep—became replaced by the brain maintaining consensus-world activity rather than alien-world activity.

Why This Matters (Even If You Disagree With It)

You can reject Gallimore’s conclusion entirely—that DMT grants access to an alternate reality—and still find the model valuable. Here’s why:

It explains DMT’s uniqueness without invoking metaphysics. If the brain once used DMT as a neuromodulator to develop parallel world-building connectivities, DMT’s phenomenological specificity is a natural consequence, not a mystery. The model makes a falsifiable prediction: DMT should be the only molecule capable of producing these characteristic alien worlds, because only DMT was present during the development of the relevant connectivities. Other psychedelics simply shift the serotonin balance differently and cannot express the alien-world set.

It reframes what “hallucination” means. Hallucination is the generation of perceptual content without extrinsic stimulation. But the model suggests the DMT experience may not be hallucination at all—it may be the reception of extrinsic data from an alternate reality, mediated by neuromodulatory switching. Whether this is “metaphysics” or “unmeasured physics” depends on your framework.

It suggests a functional explanation for DMT’s anomalous properties. Speed of onset, rapid clearance, no tolerance, non-toxicity, active transport across the blood-brain barrier—these are exactly the properties you’d expect from an endogenous neurotransmitter, not an exogenous drug. The model doesn’t require accepting DMT’s psychedelic effects as “incidental” to its proposed neural function. Instead, it proposes that the psychedelic effects are the neural function: fully immersive hallucinogenesis during which the brain switches world-building modes.

It makes testable predictions. If DMT is an ancestral neuromodulator, you should find:

Developmental differences in brain structure between DMT-naïve and DMT-experienced populations (though this would require massive longitudinal studies).
Differences in brain structure between species that produce DMT endogenously and those that don’t.
A functional role for the small amounts of DMT currently detected in the brain (likely sub-psychedelic), perhaps in neural development or maintenance of the alien-world connectivities.

What We Actually Know

Let me be clear about what’s solid and what’s speculation:

Solid:

DMT is a naturally occurring tryptamine, structurally derived from tryptophan.
DMT crosses the blood-brain barrier and may be actively transported into presynaptic terminals.
DMT acts primarily on 5HT2A receptors, with affinity between psilocin and LSD.
IV DMT in Strassman’s clinical trials reliably produces breakthrough experiences with consistent phenomenological features.
The brain possesses massive synaptic redundancy ( Edelman, 1993 ).
DMT is non-toxic, generates no tolerance, and is cleared rapidly.

Speculative:

DMT was once the primary neuromodulator for a parallel world-building mode.
The brain developed parallel thalamocortical connectivities under DMT modulation.
The alien world exists as an independently real environment.
Modern humans lost the ability to secrete DMT in psychedelic concentrations.
The pineal gland was once a site of DMT secretion and shifted to melatonin.

What I find compelling about Gallimore’s model is not the metaphysical claim (that DMT grants access to alternate realities) but the structural insight: the adult brain may contain functional connectivities that never expressed themselves because the neuromodulator that would activate them was lost during evolution. These connectivities are dormant. DMT is the key. Whether the world they build is “real” or “hallucinated” is a question we don’t yet have the tools to resolve. The neural architecture itself—the existence of parallel world-building modes—is the interesting fact, regardless of what generates the phenomenology.

When you build your understanding of consciousness from the ground up—starting from the thalamocortical system and working outward—the idea that the brain might develop multiple world-building modes depending on which neuromodulator is present is not far-fetched. It’s what you’d expect if consciousness is genuinely a world-building process rather than a world-receiving process.

The Open Questions

Several critical questions remain:

Where is DMT produced in the brain? Strassman proposes the pineal gland, but this remains unconfirmed. Barker, McIlhenny, and Strassman’s 2012 review of 69 studies found DMT in bodily fluids at sub-psychedelic levels. No one has ever measured psychedelic concentrations in the living human brain.

What is the modern function of endogenous DMT? If the molecule is produced at sub-psychedelic levels in the brain, what does it do? Proposed functions include anxiolytic effects (Jacob & Presti, 2005) and perceptual regulation (Wallach, 2009). But these seem like secondary effects. If the primary function was world-building switching, and that function was lost, then searching for a modern function may be a category error—the function may exist only in the past.

Can we measure the difference? Without a way to measure DMT concentrations during “breakthrough” experiences or during normal REM sleep, the hypothesis remains unfalsifiable in its current form. The methodology exists (CSF sampling, PET imaging of tryptamine distribution), but no study has applied it specifically to the question of endogenous DMT secretion.

What happens to the alien-world connectivities if DMT is never present? The model implies they exist as potential synapses—present in structure but not functionally expressed. Do they degrade over time? Do they persist indefinitely? This has implications for whether DMT experience in adulthood could “awaken” latent capabilities.

What’s Next

Gallimore’s model won’t resolve the question of whether DMT’s alien worlds are “real” or “hallucinated.” That question may require technologies we don’t yet possess. What it does is reframe the discussion in terms that neuroscience can work with: parallel thalamocortical connectivities, neuromodulatory switching, evolutionary developmental biology.

The most productive path forward isn’t to argue about metaphysics. It’s to ask: does the adult human brain contain expressible world-building modes other than the consensus set? If yes, what activates them? What do they produce? How do they differ structurally?

If DMT is indeed an ancestral neuromodulator that built parallel connectivities during evolution, then smoking DMT isn’t taking a drug. It’s executing a firmware update on hardware designed by a brain that once spoke a different language.

Whether that language describes an alternate reality or a latent capability of the thalamocortical system, the result is the same: a world the brain can build but currently cannot express.

Frequently Asked Questions

Is DMT really the simplest psychedelic molecule?

Yes. DMT is tryptamine with two methyl groups on the primary amine position. It contains no other chemical functionality on the indole ring. The dimethyl group prevents the nitrogen from directly interacting with the 5HT2A receptor, making DMT pharmacologically more complex than its structure suggests ( Ebersole et al., 2003 ). Yet it’s the simplest possible tryptamine structure by the standard metric.

How does Gallimore’s model differ from Strassman’s?

Strassman proposes DMT releases at death, facilitating an “exit of the soul” into an alternate reality ( Strassman, 2001 ). This is explicitly metaphysical. Gallimore’s model is framed in neuropsychological terms: parallel thalamocortical connectivities developed under DMT modulation during evolution. It doesn’t require accepting that the alien world is “real” in a metaphysical sense—only that the brain developed structural capacity to build a world it once received data about.

Has DMT been detected in the brain in psychedelic concentrations?

No. No study has ever measured psychedelic-level DMT in the living human brain. Sixty-nine studies between 1955 and 2010 found DMT in bodily fluids (urine, plasma, cerebrospinal fluid) at sub-psychedelic and variable levels ( Barker et al., 2012 ). None found a diurnal rhythm or peaks during sleep that would support the “dream molecule” hypothesis.

Can other psychedelics produce “breakthrough” experiences like DMT?

No. Gallimore’s model predicts that only DMT can produce the characteristic DMT phenomenology because only DMT was the neuromodulator present during the development of the relevant connectivities. Other psychedelics shift the 5HT1A/5HT2A balance differently and produce variable, psychologically contingent experiences, not the consistent, highly specific phenomenology of DMT breakthrough.

What would it take to test this hypothesis?

You’d need to measure endogenous DMT concentrations in the brain across development, during sleep, and across species. You’d need to compare brain connectomes between species that produce DMT endogenously at higher levels and those that don’t. You’d need to identify the molecular signature of the “alien-world” connectivities and determine whether they exist as unexpressed potential synapses in the adult brain. The tools exist—CSF sampling, PET imaging with radiolabeled tryptamines, connectome mapping—but no one has applied them to this specific question.

The Standard Model of Psychedelia Needs an Update

DMT doesn’t behave like other psychedelics. It shouldn’t be grouped with them. The discrepancy between DMT’s chemical simplicity and its phenomenological power, its pharmacological anomalousness (no tolerance, rapid clearance, active transport), and its uniquely specific and regular phenomenological content point toward a conclusion that psychedelic research has been avoiding: DMT has a true neural function, and that function is not “accidental” or “incidental” to any proposed modern role.

Gallimore’s model is speculative. It’s meant to be. But it’s speculative in a useful way—it proposes specific structural claims about thalamocortical connectivities, makes falsifiable predictions, and generates concrete experimental pathways. That’s more than most psychedelic theorizing achieves.

The hypothesis that the brain once used DMT as an ancestral neuromodulator to build parallel world-building connectivities—and then lost that ability during evolution—is bold. It’s also the best framework we have for understanding why DMT produces what DMT produces. Other models explain how the 5HT2A receptor works. Gallimore’s model attempts to explain why DMT, of all molecules, is uniquely capable of producing alien worlds at all.